Clinical trials: Anti-Retroviral Agents
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
To evaluate the safety and efficacy of Stribild®, a single tablet regimen (STR) containing fixed doses of elvitegravir (EVG)/cobicistat (COBI [GS-9350])/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) versus efavirenz…
- Trial name
- NCT01095796
- Testing
- Stribild, Atripla
- Where
- 102 sites in United States, Puerto Rico
- Volunteers
- 707 people
- Sponsor
- Gilead Sciences
HIV Infection
Raltegravir and Atazanavir Dosing Strategy Study
To compare the steady-state pharmacokinetics and short-term efficacy and safety of two dosing strategies of raltegravir and atazanavir in virologically suppressed HIV-infected adults receiving atazanavir-containing combination…
- Trial name
- SPARTA (NCT00874523)
- Testing
- atazanavir plus raltegravir
- Where
- 2 sites in Australia
- Volunteers
- 26 people
- Sponsor
- Kirby Institute
HIV Infections
Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)
Chronic human immunodeficiency virus (HIV) infection in adults continues to be characterized by increased development of resistant virus, increased transmission of resistant virus and issues associated with the long-term toxicity…
- Trial name
- NCT04001803
- Testing
- CAB LA+RPV LA
- Where
- 9 sites in United States
- Volunteers
- 115 people
- Sponsor
- ViiV Healthcare
Obesity, HIV Infections
LIROH - Liraglutide for Obesity in HIV
The goal of this single-arm, open label pilot study is to evaluate liraglutide at the recommended dosage administered subcutaneously + lifestyle counselling for the management of people living with HIV (PLWH) with obesity defined…
- Trial name
- LIROH (NCT06438146)
- Testing
- Liraglutide
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
HIV Infections
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system), or both to anti-HIV-drug therapy is safe, tolerable, and…
- Trial name
- NCT00006291
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Viruses
Implementing Long-Acting Novel Antiretrovirals
This is a 12-month, dual arm, phase 4, open-label, multi-centre study examining the implementation of LA intra-muscular (IM) drugs in clinics and decentralised community-based settings in the UK.
- Trial name
- ILANA (NCT05294159)
- Testing
- The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)
- Where
- 6 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Queen Mary University of London
HIV Infections
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
- Trial name
- NCT00059462
- Testing
- Interleukin-2 SA, HAART
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 56 people
- Sponsor
- Bayer
HIV
Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy.
- Trial name
- NCT01275625
- Testing
- HIV therapy
- Where
- 8 sites in Russia
- Volunteers
- 98 people
- Sponsor
- ViiV Healthcare
HIV Infections
Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies
Interleukin-2 (IL-2) is a protein found naturally in the blood that helps boost the immune system. The purpose of this study is to provide long-term treatment and monitoring of HIV infected people enrolled in NIAID-funded studies…
- Trial name
- NCT00311688
- Testing
- Interleukin-2
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Malaria
Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately, there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by induction of atovaquone metabolism.
- Trial name
- NCT00421473
- Testing
- Atovaquone / Proguanil
- Where
- 5 sites in Netherlands
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Cardiovascular Diseases, Platelet Aggregation, Spontaneous
Platelet Function on Abacavir and Tenofovir
This is a small observational study aimed at observing differences in platelet function in HIV patients on abacavir versus tenofovir based anti-HIV drugs.
- Conditions
- Cardiovascular Diseases, Platelet Aggregation, Spontaneous, HIV/AIDS
- Trial name
- NCT03081572
- Testing
- Platelet aggregation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Los Angeles
HIV-1 Infection
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
This study was done to look at a method of hormonal birth control, called the NuvaRing, and specific anti-HIV medications, called antiretrovirals (ARVs).
- Trial name
- NCT01903031
- Testing
- Nuvaring, EFV, ATV/r
- Where
- 21 sites in United States, Botswana and 6 more
- Volunteers
- 84 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections, Adverse Effects
Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects
The hypothesis is that participants in the intervention group will experience fewer/less intense side effects from anti-HIV medications, if they receive training sessions on the use of guided imagery, relaxation, and reframing of…
- Trial name
- NCT00696839
- Testing
- Cognitive-behavioral therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Duquesne University
HIV-1-infection
Mathematical Modeling of the HIV Transmission Risk After Initiation of Antiretroviral Therapy in naïve HIV-infected
The objective of this study is to explore the impact of initiation of ART with different regimens in naïve MSM (in the setting of acute and chronic HIV-infection) on the probability of transmission of HIV by mathematical modeling.
- Trial name
- MIAMI (NCT03183154)
- Testing
- no intervention
- Where
- Spain
- Volunteers
- 1,831 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
Background: People with HIV usually take a combination of 2 or more anti-HIV drugs daily to help manage their infection. Sometimes, however, HIV becomes resistant to these drugs, and the infection cannot be treated.
- Trial name
- NCT05582694
- Testing
- UB-421
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Antiretroviral Toxicity
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
- Trial name
- SMARTT (NCT01310023)
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 5,169 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
HIV, HIV Infections
Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients
The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression.
- Trial name
- NCT00358696
- Testing
- tenofovir
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
HIV-1
Fuzeon Viral Decay Pilot Study
In order to better understand the source(s) and the mechanism(s) of HIV persistence and to potentially lead to further suppression of HIV from viral reservoirs, we propose to examine the effect of co-administration of…
- Trial name
- NCT00334022
- Testing
- enfuvirtide
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Canadian Immunodeficiency Research Collaborative
HIV Infections
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
The purpose of this study was to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA)…
- Trial name
- NCT03635788
- Testing
- Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 456 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus I, HIV Infection
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily.
- Trial name
- NCT00082394
- Testing
- Trizivir, atazanavir, Combivir
- Where
- 45 sites in United States, Mexico
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.